Corcept Therapeutics announced that the treatment phase of its CATALYST study met its primary endpoint, demonstrating positive results for Korlym in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes. Patients receiving Korlym showed a clinically meaningful and statistically significant improvement in hemoglobin A1c, with a decrease of 1.47 percent from baseline compared to a 0.15 percent decrease in the placebo group (p-value: < 0.0001).
The CATALYST study's prevalence phase previously identified that 23.8 percent of patients with difficult-to-control type 2 diabetes also have hypercortisolism, indicating a larger treatable patient population than previously assumed. This finding, combined with the positive treatment results, supports expanded screening and treatment for this patient group.
The safety profile of Korlym in the study was consistent with its existing label, with no new side effects or adverse events identified. These results are expected to prompt increased physician awareness and more effective treatment for patients struggling with difficult-to-control type 2 diabetes due to hypercortisolism.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.